Jointown Pharmaceutical Group Co Ltd (600998) Valuation & Financial Model
Interactive Discounted Cash Flow (DCF) model for Jointown Pharmaceutical Group Co Ltd (SSE:600998), currently being evaluated. In 2025, Jointown Pharmaceutical Group Co Ltd generated $161.39 Billion in revenue and $2.04 Billion in free cash flow. Explore projected intrinsic value assumptions based on institutional-grade macro metrics.
Valuation Methodology & Recent Performance
The financial model for Jointown Pharmaceutical Group Co Ltd is calculated using an institutional discounted cash flow (DCF) engine utilizing recent operational metrics:
- Current Price: N/A
- Recent Revenue (2025): $161.39 Billion
- Free Cash Flow (2025): $2.04 Billion
- Discount Rate (WACC): Derived using the Risk-Free Rate (e.g., 10Y Gov Bond) plus an Equity Risk Premium based on market volatility and stock price variance.
- Terminal Value: Projected using a perpetual growth model bounded by long-term macroeconomic estimates.